Biotech | December 08, 2021
SPARC partners with Visiox for ophthalmic drugs
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
Anti-malaria API facility will be operational in 15-18 months
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
The agreement will help ensure wider reach and access to patients in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Subscribe To Our Newsletter & Stay Updated
